FDA Noxafil Approval Delayed By Last-Minute Label, Data Integrity Issues
FDA overshot the user fee goal on Schering-Plough's Noxafil (posaconazole) to address labeling and data integrity issues that arose late in the review of the antifungal, FDA review documents indicate
You may also be interested in...
Schering-Plough's Noxafil (posaconazole) is the first antifungal approved by FDA for the prevention of invasive fungal infections caused by Aspergillus species
An independent analysis of FDA's first-cycle review performance provides support for the agency's request for additional funding for pre-submission meetings
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.